You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

Details for Patent: 7,932,241


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 7,932,241 protect, and when does it expire?

Patent 7,932,241 protects ZOMETA and RECLAST and is included in two NDAs.

Protection for RECLAST has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has twenty-six patent family members in twenty-two countries.

Summary for Patent: 7,932,241
Patent landscape, scope, and claims:
Title:Pharmaceutical products comprising bisphosphonates
Abstract: A pharmaceutical product comprises a container containing a bisphosphonate solution, in which at least the internal surface of the container comprises a plastic material and in which the container is heat sterilisable, and which is in the form of a ready to use infusion solution, for administration of the bisphosphonate to a patient in need of bisphosphonate treatment.
Inventor(s): Glausch; Alexandra (Weil am Rhein, DE), Loffler; Rolf (Freiburg, DE), Sigg; Juergen (Loerrach, DE)
Assignee: Novartis AG (Basel, CH)
Application Number:10/570,339
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,932,241
Patent Claim Types:
see list of patent claims
Formulation; Compound; Process;

More… ↓

⤷  Subscribe


Drugs Protected by US Patent 7,932,241

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Novartis ZOMETA zoledronic acid INJECTABLE;INTRAVENOUS 021223-003 Jun 17, 2011 DISCN Yes No 7,932,241 ⤷  Subscribe Y ⤷  Subscribe
Sandoz RECLAST zoledronic acid INJECTABLE;INTRAVENOUS 021817-001 Apr 16, 2007 AP RX Yes Yes 7,932,241*PED ⤷  Subscribe Y ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 7,932,241

PCT Information
PCT FiledSeptember 17, 2004PCT Application Number:PCT/EP2004/010470
PCT Publication Date:March 24, 2005PCT Publication Number: WO2005/025551

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.